Common Contracts

Nissan Chemical Industries and Teijin Pharma License Ex-Japan Rights for Atrial Fibrillation/Flutter Drug to Bristol-Myers Squibb

Licensing Agreement • March 11th, 2009

• Contract Type
  Licensing Agreement
• Filed
  March 11th, 2009

Nissan Chemical Industries, Ltd. (Headquarters: Chiyoda-ku, Tokyo; President: Kojiro Kinoshita) (“Nissan Chemical”) and Teijin Pharma Limited (Headquarters: Chiyoda-ku, Tokyo; President: Osamu Nishikawa) (“Teijin Pharma”) have concluded a licensing agreement with Bristol-Myers Squibb Company (NYSE:BMY) (Headquarters: New York City, New York, US; Chairman and CEO: James M. Cornelius) (“BMS”) for the novel atrial fibrillation and flutter treatment and preventive drug NTC-801, which was discovered by Nissan Chemical and is being jointly developed in Japan by Nissan Chemical and Teijin Pharma.